إعلان
إعلان

NRXP

NRXP logo

NRX Pharmaceuticals, Inc. Common Stock

2.33
USD
برعاية
-0.12
-5.02%
٠٨ يناير, ١٥:٥٩ UTC -5
مغلق
exchange

بعد الإغلاق

2.35

+0.02
+0.77%

تقارير أرباح NRXP

النسبة الإيجابية المفاجئة

NRXP تفوق 7 من 14 آخر التقديرات.

50%

التقرير التالي

بيانات التقرير القادم
١٦ مارس ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
$9.51M
/
$0.00
التغير الضمني من Q3 25 (Revenue/ EPS)
+3830.37%
/
-100.00%
التغير الضمني من Q4 24 (Revenue/ EPS)
--
/
-100.00%

NRX Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On ١٤ نوفمبر ٢٠٢٥, NRXP reported earnings of -0.50 USD per share (EPS) for Q3 25, missing the estimate of -0.08 USD, resulting in a -476.70% surprise. Revenue reached 242.00 ألف, compared to an expected 6.96 مليون, with a -96.52% difference. The market reacted with a -15.26% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 6 المحللين forecast an EPS of 0.00 USD, with revenue projected to reach 9.51 مليون USD, implying an نقصان of -100.00% EPS, and زيادة of 3830.37% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Citius Pharmaceuticals Inc. Common
Report Date
٢٦ ديسمبر ٢٠٢٥ إلى ربع سنوي4 25
تقدير
-$0.49
الفعلي
-
مفاجئة
-
الأسئلة الشائعة
For Q3 2025, NRX Pharmaceuticals, Inc. Common Stock reported EPS of -$0.50, missing estimates by -476.7%, and revenue of $242.00K, -96.52% below expectations.
The stock price moved down -15.26%, changed from $2.49 before the earnings release to $2.11 the day after.
The next earning report is scheduled for ١٦ مارس ٢٠٢٦.
Based on 6 المحللين, NRX Pharmaceuticals, Inc. Common Stock is expected to report EPS of -- and revenue of $9.51M for Q4 2025.
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان